<DOC>
	<DOC>NCT01218659</DOC>
	<brief_summary>Study to compare the efficacy and safety of AT1001 and enzyme replacement therapy (ERT) in male and female patients with Fabry disease who are currently receiving ERT and who have AT1001-responsive GLA mutations.</brief_summary>
	<brief_title>Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease</brief_title>
	<detailed_description />
	<mesh_term>Fabry Disease</mesh_term>
	<criteria>Male or female between the ages of 16 and 74 diagnosed with Fabry disease Confirmed GLA mutation that has shown to be responsive to AT1001 in vitro Subject has been on ERT for at least 12 months before Visit 2 Dose level and regimen of ERT have been stable for 3 months before Visit 2 and is at least 80% of the currently labeled dose and regimen for this time period GFR ≥ 30mL/min/1.73 m2 Subjects taking angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) must be on a stable dose for at least 4 weeks before Visit 1 Women who can become pregnant and all men agree to be sexually abstinent or use medically accepted methods of birth control throughout the duration of the study and for up to 30 days after last dose of study medication * For sites in Italy: Women who can become pregnant and all men, agree to plan (or have their partner plan) with his/her physician a birth control strategy (or method) in order to avoid pregnancy throughout the duration of the study and for up to 30 days after the last dose of study medication Subject is willing and able to provide written informed consent and assent if applicable Subject has undergone, or is scheduled to undergo, kidney transplantation or any other solid organ transplantation Subject is on regular dialysis that is specifically for the treatment of chronic kidney disease Subject has had a documented transient ischemic attack, stroke, unstable angina, or myocardial infarction within the 3 months before Visit 1 Subject has clinically significant unstable cardiac disease in the opinion of the investigator (e.g., cardiac disease requiring active management, such as symptomatic arrhythmia, unstable angina, or NYHA class III or IV congestive heart failure) Pregnant or breastfeeding History of allergy or sensitivity to study medication (including excipients) or other iminosugars (e.g., miglustat, miglitol) Subject has absolute contraindication to iohexol and/or inability to undergo iohexol GFR testing Subject requires treatment with Glyset® (miglitol), or Zavesca® (miglustat) Subject received any investigational/experimental drug, biologic or device within 30 days of Visit 1 Any intercurrent illness or condition that may preclude the subject from fulfilling the protocol requirements or suggests to the investigator that the subject may have an unacceptable risk by participating in this study Otherwise unsuitable for the study, in the opinion of the investigator</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Fabry Disease</keyword>
</DOC>